Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor for Stem Cell Mobilization in NHL and MM
NCT00395967Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Apr 2005
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Sanofi. Primary endpoint: Number of Patients Who Achieved >=2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days. Started Apr 2005; status: terminated.
02
Drugs
plerixafor
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00395967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395967.